Kombi-Kalz

Colecalciferol and Calcium carbonate, the active ingredients in Kombi-Kalz, are a vitamin D and calcium supplement presented as an oral tablet for oral use. They help correct vitamin D and calcium deficiencies and support bone health in adults and children at risk of low mineral intake.

GNH USA supplies Kombi-Kalz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for cross‑border distribution. This enables reliable access to the product in diverse markets.

Kombi‑Kalz is used to address nutritional deficiencies of calcium and vitamin D, supporting skeletal health. - Calcium deficiency: helps restore normal calcium levels and promotes bone mineralization. - Vitamin D deficiency: provides vitamin D3 to enhance intestinal calcium absorption. - Osteopenia risk: supports bone density maintenance in individuals at risk of bone loss.

Oral administration of Kombi‑Kalz may be associated with several adverse reactions, ranging from mild to rare serious events.

Common Side Effects: - Nausea: mild stomach upset. - Constipation: reduced bowel movements. - Flatulence: increased intestinal gas. - Hypercalcemia symptoms: mild fatigue or headache.

Serious or Rare Side Effects: - Hypercalcemia: severe elevated calcium levels causing confusion, arrhythmia, or cardiac issues. - Kidney stones: calcium precipitation in the renal tract. - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Hypervitaminosis D: toxicity leading to vomiting, weakness, and severe metabolic disturbances.

Before using Kombi‑Kalz, consider the following precautions to ensure safe and effective therapy. - Assess calcium status: evaluate serum calcium before initiating therapy. - Monitor vitamin D levels: periodic testing helps avoid excess. - Renal impairment: adjust use in patients with reduced kidney function. - Hyperparathyroidism: use with caution as calcium metabolism is altered. - Concomitant calcium‑binding drugs: avoid simultaneous use as they may reduce absorption. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Kombi‑Kalz can interact with other medicines; awareness of these interactions helps prevent reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Thiazide diuretics: may increase risk of hypercalcemia. - Vitamin D analogues: additive effect leading to excess calcium. - Calcium carbonate with iron supplements: reduces iron absorption.

Moderate Interactions (Monitor Closely): - Bisphosphonates: calcium may interfere with absorption; separate dosing by at least 2 hours. - Antacids containing aluminum or magnesium: may affect calcium uptake. - Corticosteroids: may increase calcium loss, requiring monitoring.